Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin

NCT02499770 is registered in ClinicalTrials.gov with G1 Therapeutics, Inc. as lead sponsor.

NCT NCT02499770
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02499770 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin
Lead sponsor
G1 Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
June 26, 2015
Completion date
February 22, 2019
Enrollment
122 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer